H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)

August 26, 2026 6:42 AM

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and $35.00 price target on Corbus Pharmaceuticals (NASDAQ: CRBP).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found